CIK 0001782107
- Emerging growth company
Onconetix, Inc.
Sign in to watch- Ticker
- ONCO
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- Phone
- +1 513-620-4101
- Business address
- 201 E. FIFTH STREET, SUITE 1900, CINCINNATI, OH, 45202
- Former names
- Blue Water Biotech, Inc., Blue Water Vaccines Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-04-21 | HRT FINANCIAL LP 10% owner | Sale | −49,710 | $0.69 | $34K | 33,649 |
| 2026-04-20 | HRT FINANCIAL LP 10% owner | Sale | −94,462 | $0.75 | $71K | 83,359 |
| 2026-04-17 | HRT FINANCIAL LP 10% owner | Purchase | +34,636 | $0.73 | $25K | 177,821 |
| 2026-04-16 | HRT FINANCIAL LP 10% owner | Sale | −53,867 | $0.73 | $39K | 143,185 |
| 2026-04-15 | HRT FINANCIAL LP 10% owner | Purchase | +92,554 | $0.76 | $70K | 197,052 |
| 2026-04-14 | HRT FINANCIAL LP 10% owner | Purchase | +74,350 | $0.77 | $57K | 104,498 |
| 2025-08-15 | Oakley Andrew John Director | Other acquisition | +20 | 20 | ||
| 2025-08-15 | Oakley Andrew John Director | Grant or award | +618 | 638 | ||
| 2025-08-15 | Tarsh Simon Director | Other acquisition | +39 | 40 | ||
| 2025-08-15 | Tarsh Simon Director | Grant or award | +618 | 658 | ||
| 2025-08-15 | Meier Thomas Director | Other acquisition | +39 | 39 | ||
| 2025-08-15 | Meier Thomas Director | Grant or award | +618 | 657 | ||
| 2025-08-15 | Ramdeen Timothy R. Director | Other acquisition | +39 | 40 | ||
| 2025-08-15 | Ramdeen Timothy R. Director | Grant or award | +618 | 658 | ||
| 2025-07-14 | Altos Venture AG 10% owner | Other acquisition | +241,514 | 273,230 | ||
| 2025-07-14 | Altos Venture AG 10% owner | Other disposition · Make-whole right (right to acquire) | −241,514 | 0 | ||
| 2025-03-23 | Oakley Andrew John Director | Grant or award | +1,709 | 1,709 | ||
| 2024-12-20 | Schiess Ralph Interim CEO, CSO | Grant or award | +177,462 | 673,365 | ||
| 2024-12-20 | Bruhlmann Christian Chief Strategy Officer | Grant or award | +177,462 | 611,372 | ||
| 2024-09-26 | Tarsh Simon Director | Grant or award | +3,318 | 3,477 |
Page 1 of 3 · 60 trades